Soonmyung Paik logo Yonsei Cancer Center, Yonsei University College of Medicine logo

Soonmyung Paik

Professor and Director of Yonsei Genome Center, Yonsei Cancer Center (South Korea)


Dr. Soonmyung Paik was the recipient of the 2010 Susan Komen Foundation Brinker Award for Scientific Distinction for Clinical Science.  He graduated from Yonsei University College of Medicine, Seoul, Korea in 1981, after his training in anatomic pathology, postdoc fellowship at NCI, and tenure at Lombardi Cancer Center, he served NSABP as the Director of the Division of Pathology since 1996. Since 2013, he has also served as the professor of medical oncology and director of Yonsei Genome Center at Yonsei University College of Medicine.

Dr Paik’s main research interest is in developing predictive markers for treatment response in breast cancer. In 2004 his lab, in collaboration with Genomic Health Inc, has developed a multigene based test called OncotypeDx that is used to predict prognosis and response to chemotherapy in node-negative hormone-receptor-positive breast cancer.


Why WIN

“To contribute to the development of genome directed personalized cancer treatment and to help enhance the role of Yonsei Cancer Center in genomic oncology.”

Soonmyung Paik logo

Soonmyung Paik

Professor and Director of Yonsei Genome Center, Yonsei Cancer Center (South Korea)


Yonsei Cancer Center, Yonsei University College of Medicine logo

Dr. Soonmyung Paik was the recipient of the 2010 Susan Komen Foundation Brinker Award for Scientific Distinction for Clinical Science.  He graduated from Yonsei University College of Medicine, Seoul, Korea in 1981, after his training in anatomic pathology, postdoc fellowship at NCI, and tenure at Lombardi Cancer Center, he served NSABP as the Director of the Division of Pathology since 1996. Since 2013, he has also served as the professor of medical oncology and director of Yonsei Genome Center at Yonsei University College of Medicine.

Dr Paik’s main research interest is in developing predictive markers for treatment response in breast cancer. In 2004 his lab, in collaboration with Genomic Health Inc, has developed a multigene based test called OncotypeDx that is used to predict prognosis and response to chemotherapy in node-negative hormone-receptor-positive breast cancer.


Why WIN

“To contribute to the development of genome directed personalized cancer treatment and to help enhance the role of Yonsei Cancer Center in genomic oncology.”